# Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)

> **NCT00483704** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1935 (actual)

## Conditions studied

- Migraines

## Interventions

- **DRUG:** Telcagepant 140 mg
- **DRUG:** Talcagepant 280 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00483704
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08-14
- **Primary completion:** 2009-03-25
- **Final completion:** 2009-03-25
- **Target enrollment:** 1935 (ACTUAL)
- **Last updated:** 2018-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00483704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00483704, "Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00483704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*